| A Message from Biostem Technologies
| BSEM: From Profitable Regenerative Leader to Advanced Wound Care Powerhouse with a Nasdaq Uplisting on the Horizon. | | BioStem Technologies (OTCQB: BSEM) continues to separate itself from the small-cap MedTech pack with seven straight profitable quarters, FDA-registered manufacturing, and clinically proven BioREtain® technology that drives superior healing outcomes in diabetic foot ulcers.
The recent acquisition of BioTissue's surgical and wound care business adds $29 million in revenue, a national sales network, and immediate access to hospital and surgical settings, creating a direct path into acute and advanced wound care markets.
With early adoption reflected in 40% year-over-year unit growth, a robust $300–$350 million market opportunity, and a potential Nasdaq uplisting in mid-2026, BSEM is executing on every element of a high-growth MedTech strategy.
With a $25.50 price target from Zacks, BSEM stands out as a small-cap MedTech name with significant upside potential, especially as it prepares for a potential Nasdaq uplisting in 2026.
Strong financial discipline, expanding commercial reach, and validated clinical results make BSEM a rare small-cap story to keep an eye on.
See how BSEM is redefining the future of advanced and acute wound care in 2026 while building shareholder value |
|
0 التعليقات:
إرسال تعليق